《国际指南：静脉注射免疫球蛋白在治疗Rh和ABO新生儿溶血病中的作用》解读

doi:10.7499/j.issn.1008-8830.2205158

Abstract
Figure/Table
References(35)
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (511 KB) HTML
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract International guidelines regarding the role of intravenous immunoglobulin (IVIG) in the management of Rh- and ABO-mediated haemolytic disease of the newborn was drafted by an international panel of experts in the fields of hematology, neonatology, and blood transfusion and was published in British Journal of Haematology on March 16, 2022. The guidelines summarize the evidence-based practice of IVIG in Rh- and ABO-mediated haemolytic disease of the newborn and propose related recommendations. The guidelines recommend that IVIG should not be applied as a routine treatment regimen for Rh- and ABO-mediated haemolytic disease of the newborn in order to reduce exchange transfusion (ET), and the best time to apply IVIG remains unclear in the situations where hyperbilirubinaemia is severe (approaching or exceeding the ET threshold) or ET cannot be implemented. These guidelines are formulated with rigorous methods, but with the lower quality of evidence.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Fang-Jun
	HE Yang
	TANG Jun
	ZHANG Meng
	CHEN Jian
	MU De-Zhi

Key words： Intravenous immunoglobulin Haemolytic disease of the newborn International guideline Neonate

Received: 27 May 2022

Cite this article:

HUANG Fang-Jun,HE Yang,TANG Jun et al. Interpretation of "International guidelines regarding the role of IVIG in the management of Rh- and ABO-mediated haemolytic disease of the newborn"[J]. CJCP, 2022, 24(11): 1183-1188.

URL:

http://www.zgddek.com/EN/10.7499/j.issn.1008-8830.2205158 OR http://www.zgddek.com/EN/Y2022/V24/I11/1183

	Webb J, Delaney M. Red blood cell alloimmunization in the pregnant patient[J]. Transfus Med Rev, 2018, 32(4): 213-219. PMID: 30097223. DOI: 10.1016/j.tmrv.2018.07.002.
	Delaney M, Matthews DC. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn[J]. Hematology Am Soc Hematol Educ Program, 2015, 2015: 146-151. PMID: 26637714. DOI: 10.1182/asheducation-2015.1.146.
	3 Kliegman RM, Nelson WE. Nelson Textbook of Pediatrics[M]. 19th ed. Philadelphia, PA, USA: Elsevier/Saunders, 2011: 615-619.
	Fasano RM. Hemolytic disease of the fetus and newborn in the molecular era[J]. Semin Fetal Neonatal Med, 2016, 21(1): 28-34. PMID: 26589360. DOI: 10.1016/j.siny.2015.10.006.
	5 邵肖梅, 叶鸿瑁, 丘小汕, 等. 实用新生儿学[M]. 5版. 北京: 人民卫生出版社, 2019.
	Lieberman L, Callum J, Cohen R, et al. Impact of red blood cell alloimmunization on fetal and neonatal outcomes: a single center cohort study[J]. Transfusion, 2020, 60(11): 2537-2546. PMID: 32893897. DOI: 10.1111/trf.16061.
	Pillai A, Pandita A, Osiovich H, et al. Pathogenesis and management of indirect hyperbilirubinemia in preterm neonates less than 35 weeks: moving toward a standardized approach[J]. Neoreviews, 2020, 21(5): e298-e307. PMID: 32358143. DOI: 10.1542/neo.21-5-e298.
	Zhang M, Tang J, He Y, et al. Systematic review of global clinical practice guidelines for neonatal hyperbilirubinemia[J]. BMJ Open, 2021, 11(1): e040182. PMID: 33468526. PMCID: PMC7817798. DOI: 10.1136/bmjopen-2020-040182.
	Lieberman L, Lopriore E, Baker JM, et al. International guidelines regarding the role of IVIG in the management of Rh- and ABO-mediated haemolytic disease of the newborn[J]. Br J Haematol, 2022, 198(1): 183-195. PMID: 35415922. DOI: 10.1111/bjh.18170.
	10 周奇, 邢丹, 李沁原, 等. 指南解读类文献报告规范的制订指南 (RIGHT for INT)[J]. 中国循证医学杂志, 2022, 22(5): 497-507. DOI: 10.7507/1672-2531.202201137.
	Zwiers C, Scheffer-Rath ME, Lopriore E, et al. Immunoglobulin for alloimmune hemolytic disease in neonates[J]. Cochrane Database Syst Rev, 2018, 3(3): CD003313. PMID: 29551014. PMCID: PMC6494160. DOI: 10.1002/14651858.CD003313.pub2.
	Louis D, More K, Oberoi S, et al. Intravenous immunoglobulin in isoimmune haemolytic disease of newborn: an updated systematic review and meta-analysis[J]. Arch Dis Child Fetal Neonatal Ed, 2014, 99(4): F325-F331. PMID: 24514437. DOI: 10.1136/archdischild-2013-304878.
	Elalfy MS, Elbarbary NS, Abaza HW. Early intravenous immunoglobin (two-dose regimen) in the management of severe Rh hemolytic disease of newborn: a prospective randomized controlled trial[J]. Eur J Pediatr, 2011, 170(4): 461-467. PMID: 20924607. DOI: 10.1007/s00431-010-1310-8.
	Tanyer G, Siklar Z, Dallar Y, et al. Multiple dose IVIG treatment in neonatal immune hemolytic jaundice[J]. J Trop Pediatr, 2001, 47(1): 50-53. PMID: 11245352. DOI: 10.1093/tropej/47.1.50.
	Beken S, Hirfanoglu I, Turkyilmaz C, et al. Intravenous immunoglobulin G treatment in ABO hemolytic disease of the newborn, is it myth or real?[J]. Indian J Hematol Blood Transfus, 2014, 30(1): 12-15. PMID: 24554813. PMCID: PMC3921323. DOI: 10.1007/s12288-012-0186-3.
	Demirel G, Akar M, Celik IH, et al. Single versus multiple dose intravenous immunoglobulin in combination with LED phototherapy in the treatment of ABO hemolytic disease in neonates[J]. Int J Hematol, 2011, 93(6): 700-703. PMID: 21617887. DOI: 10.1007/s12185-011-0853-4.
	American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation[J]. Pediatrics, 2004, 114(1): 297-316. PMID: 15231951. DOI: 10.1542/peds.114.1.297.
	18 The GRADE Working Group. Grading of recommendations, assessment, development, and evaluations (GRADE)[EB/OL].[2022-05-06]. https://www.gradeworkinggroup.org/#pub.
	Norris SL; RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group. A reporting tool for practice guidelines in health care: the RIGHT statement[J]. Ann Intern Med, 2017, 166(2): 128-132. PMID: 27893062. DOI: 10.7326/M16-1565.
	20 National Institute for Health and Care Excellence. Jaundice in newborn babies under 28 days[EB/OL]. [2022-05-06]. https://www.nice.org.uk/guidance/CG98/evidence.
	21 Barrington KJ, Sankaran K, Canadian Paediatric Society, et al. Guidelines for detection, management and prevention of hyperbilirubinemia in term and late preterm newborn infants[J]. Paediatr Child Health, 2007, 12(suppl_B): 1B-12B. DOI: 10.1093/pch/12.suppl_B.1B.
	Romagnoli C, Barone G, Pratesi S, et al. Italian guidelines for management and treatment of hyperbilirubinaemia of newborn infants ≥ 35 weeks' gestational age[J]. Ital J Pediatr, 2014, 40(1): 11. PMID: 24485088. PMCID: PMC4015911. DOI: 10.1186/1824-7288-40-11.
	23 中华医学会儿科学分会新生儿学组, 《中华儿科杂志》编辑委员会. 新生儿高胆红素血症诊断和治疗专家共识[J]. 中华儿科杂志, 2014, 52(10): 745-748. DOI: 10.3760/cma.j.issn.0578-1310.2014.10.006.
	oban A, Türkmen MK, Gürsoy T. Turkish Neonatal Society guideline to the approach, follow-up, and treatment of neonatal jaundice[J]. Turk Pediatri Ars, 2018, 53(Suppl 1): S172-S179. PMID: 31236030. PMCID: PMC6568284. DOI: 10.5152/TurkPediatriArs.2018.01816.
	Sánchez-Redondo Sánchez-Gabriel MD, Leante Castellanos JL, Benavente Fernández I, et al. Guidelines for prevention, detection and management of hyperbilirubinaemia in newborns of 35 or more weeks of gestation[J]. An Pediatr (Barc), 2017, 87(5): 294.e1-294.e8. PMID: 28526241. DOI: 10.1016/j.anpedi.2017.03.006.
	Kaplan M, Merlob P, Regev R. Israel guidelines for the management of neonatal hyperbilirubinemia and prevention of kernicterus[J]. J Perinatol, 2008, 28(6): 389-397. PMID: 18322551. DOI: 10.1038/jp.2008.20.
	27 Queensland Government . Neonatal jaundice[EB/OL].[2022-05-06]. https://www.health.qld.gov.au/__data/assets/pdf_file/0018/142038/g-jaundice.pdf.
	28 Section M. Management of neonatal jaundice[EB/OL]. [2022-05-06].
	Bratlid D, Nakstad B, Hansen TW. National guidelines for treatment of jaundice in the newborn[J]. Acta Paediatr, 2011, 100(4): 499-505. PMID: 21114525. DOI: 10.1111/j.1651-2227.2010.02104.x.
	30 Swiss Society of Neonatology. Assessment and treatment of jaundiced newborn infants 35 0/7 or more weeks of gestation[EB/OL]. [2022-05-06]. https://www.neonet.ch/application/files/6915/6879/9379/2006_Bili-Empfehlungen_e_final.pdf.
	Singh-Grewal D, Kemp A, Wong M. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions[J]. Arch Dis Child, 2006, 91(8): 651-654. PMID: 16638785. PMCID: PMC2083046. DOI: 10.1136/adc.2005.078733.
	32 Henrickson SE, Law CK. Adverse effects of different formulations of intravenous immunoglobulin[J]. J Allergy Clin Immunol, 2015, 135(Suppl 2): AB92. DOI: 10.1016/j.jaci.2014.12.1232.
	Kumar A, Kapoor R, Basu S. Apnea as a complication of intravenous immunoglobulin therapy in a neonate[J]. Indian J Pediatr, 2014, 81(12): 1415. PMID: 24944148. DOI: 10.1007/s12098-014-1509-1.
	Christensen RD, Ilstrup SJ, Baer VL, et al. Increased hemolysis after administering intravenous immunoglobulin to a neonate with erythroblastosis fetalis due to Rh hemolytic disease[J]. Transfusion, 2015, 55(6): 1365-1366. PMID: 26074177. DOI: 10.1111/trf.13104.
	Figueras-Aloy J, Rodríguez-Miguélez JM, Iriondo-Sanz M, et al. Intravenous immunoglobulin and necrotizing enterocolitis in newborns with hemolytic disease[J]. Pediatrics, 2010, 125(1): 139-144. PMID: 19948572. DOI: 10.1542/peds.2009-0676.